{
    "clinical_study": {
        "@rank": "23425", 
        "arm_group": [
            {
                "arm_group_label": "Placebo-Control", 
                "arm_group_type": "Placebo Comparator", 
                "description": "The placebo-control group will take two placebo softgel capsules every day for 8 weeks."
            }, 
            {
                "arm_group_label": "Low-Dose Vitamin K2 (45 mcg/d)", 
                "arm_group_type": "Active Comparator", 
                "description": "The low-dose vitamin K2 group will take one 45-mcg vitamin K2 softgel capsule and one placebo softgel capsule every day for 8 weeks."
            }, 
            {
                "arm_group_label": "High-Dose Vitamin K2 (90 mcg/d)", 
                "arm_group_type": "Active Comparator", 
                "description": "The high-dose vitamin K2 group will take two 45-mcg vitamin K2 softgel capsules every day for 8 weeks."
            }
        ], 
        "brief_summary": {
            "textblock": "Given that glutamate carboxylation or decarboxylation is key to the metabolic role of\n      osteocalcin (at least in mouse models) and that carboxylation is vitamin K dependent, it is\n      critical to isolate the effect of vitamin K manipulation on carboxylation of osteocalcin and\n      its subsequent effect on glucose metabolism in clinical trials. The purpose of this\n      randomized, double-blind, placebo-controlled clinical trial in obese children is to\n      determine whether eight weeks of daily supplementation with vitamin K2 (menaquinone-7) can\n      improve markers in blood associated with diabetes risk."
        }, 
        "brief_title": "Effect of Vitamin K Supplementation on Markers of Diabetes Risk in Obese Children", 
        "condition": [
            "Obesity", 
            "Insulin Resistance", 
            "Insulin Sensitivity", 
            "Beta-Cell Dysfunction", 
            "Prediabetes"
        ], 
        "condition_browse": {
            "mesh_term": [
                "Insulin Resistance", 
                "Obesity", 
                "Glucose Intolerance", 
                "Prediabetic State"
            ]
        }, 
        "eligibility": {
            "criteria": {
                "textblock": "Inclusion Criteria:\n\n          -  Age 8 to 11 years\n\n          -  Obese but otherwise healthy (obese is defined as having body mass index greater than\n             or equal to 95th percentile for children of same age and sex)\n\n          -  Sedentary (no regular physical activity or sports program greater than one hour per\n             week)\n\n          -  Subject and parent/guardian understands the study protocol and agrees to comply with\n             it\n\n          -  Informed Consent Form signed by the parent/guardian and assent signed by the subject\n\n        Exclusion Criteria:\n\n          -  Subjects using vitamin supplements containing vitamin k\n\n          -  Subjects with (a history of) metabolic or gastrointestinal diseases including hepatic\n             disorders\n\n          -  Subjects presenting chronic degenerative and/or inflammatory diseases\n\n          -  Subjects receiving systemic treatment or topical treatment likely to interfere with\n             evaluation of the study parameters (salicylates, antibiotics)\n\n          -  Subjects receiving corticosteroid treatment\n\n          -  Subjects using oral anticoagulants\n\n          -  Subjects with a history of soy allergy\n\n          -  Subjects who have participated in a clinical study more recently than one month\n             before the current study"
            }, 
            "gender": "Both", 
            "healthy_volunteers": "Accepts Healthy Volunteers", 
            "maximum_age": "11 Years", 
            "minimum_age": "8 Years"
        }, 
        "enrollment": {
            "#text": "60", 
            "@type": "Anticipated"
        }, 
        "firstreceived_date": "October 24, 2013", 
        "has_expanded_access": "No", 
        "id_info": {
            "nct_id": "NCT01972113", 
            "org_study_id": "Pro00000912"
        }, 
        "intervention": [
            {
                "arm_group_label": "Placebo-Control", 
                "description": "two placebo softgel capsules per day (for 8 weeks) containing no vitamin K2 (menaquinone-7)", 
                "intervention_name": "Placebo-Control", 
                "intervention_type": "Dietary Supplement"
            }, 
            {
                "arm_group_label": "Low-Dose Vitamin K2 (45 mcg/d)", 
                "description": "one 45-mcg vitamin K2 (menaquinone-7) softgel capsule per day and one placebo softgel per day (containing no menaquinone-7) for 8 weeks", 
                "intervention_name": "Low-Dose Vitamin K2 (menaquinone-7; 45 mcg/d)", 
                "intervention_type": "Dietary Supplement", 
                "other_name": "menaquinone-7"
            }, 
            {
                "arm_group_label": "High-Dose Vitamin K2 (90 mcg/d)", 
                "description": "two 45-mcg vitamin K2 (menaquinone-7) softgel capsules per day for 8 weeks", 
                "intervention_name": "High-Dose Vitamin K2 (menaquinone-7; 90 mcg/d)", 
                "intervention_type": "Dietary Supplement", 
                "other_name": "menaquinone-7"
            }
        ], 
        "intervention_browse": {
            "mesh_term": [
                "Vitamin K", 
                "Vitamins", 
                "Vitamin K 2", 
                "Vitamin MK 7"
            ]
        }, 
        "is_fda_regulated": "No", 
        "keyword": [
            "Vitamin K", 
            "Vitamin K2", 
            "Menaquinone-7", 
            "Osteocalcin", 
            "Children", 
            "Obesity", 
            "Insulin resistance", 
            "Insulin sensitivity", 
            "Beta-cell function", 
            "Prediabetes"
        ], 
        "lastchanged_date": "October 24, 2013", 
        "location": {
            "facility": {
                "address": {
                    "city": "Augusta", 
                    "country": "United States", 
                    "state": "Georgia", 
                    "zip": "30909"
                }, 
                "name": "Medical College of Georgia; Georgia Regents University"
            }, 
            "investigator": {
                "last_name": "Norman K Pollock, Ph.D.", 
                "role": "Principal Investigator"
            }, 
            "status": "Recruiting"
        }, 
        "location_countries": {
            "country": "United States"
        }, 
        "number_of_arms": "3", 
        "official_title": "Efficacy and Optimal Dose Finding Study of Vitamin K on Glucose Metabolism in Children at Risk for Diabetes", 
        "overall_contact": {
            "email": "npollock@gru.edu", 
            "last_name": "Norman K Pollock, Ph.D.", 
            "phone": "706-721-5424"
        }, 
        "overall_official": {
            "affiliation": "Department of Pediatrics, Medical College of Georgia, Georgia Regents University", 
            "last_name": "Norman K Pollock, Ph.D.", 
            "role": "Principal Investigator"
        }, 
        "overall_status": "Recruiting", 
        "oversight_info": {
            "authority": "United States: Institutional Review Board", 
            "has_dmc": "Yes"
        }, 
        "phase": "Phase 2/Phase 3", 
        "primary_completion_date": {
            "#text": "August 2014", 
            "@type": "Anticipated"
        }, 
        "primary_outcome": [
            {
                "description": "The first primary aim is to determine if the vitamin K-induced change in carboxylation of osteocalcin effects insulin sensitivity in a dose-dependent manner. Insulin sensitivity will be calculated from plasma insulin and glucose concentrations measured during a two-hour oral glucose tolerance test by using the oral glucose minimal model.", 
                "measure": "Change in insulin sensitivity", 
                "safety_issue": "No", 
                "time_frame": "8 weeks"
            }, 
            {
                "description": "The second primary aim is to determine if the vitamin K-induced change in carboxylation of osteocalcin effects beta-cell function in a dose-dependent manner. Beta-cell function, as assessed by dynamic beta-cell responsitivity, will be calculated from plasma glucose and C-peptide concentrations measured during a two-hour oral glucose tolerance test by using the oral C-peptide minimal model.", 
                "measure": "Change in beta-cell function", 
                "safety_issue": "No", 
                "time_frame": "8 weeks"
            }
        ], 
        "reference": [
            {
                "PMID": "21508147", 
                "citation": "Pollock NK, Bernard PJ, Gower BA, Gundberg CM, Wenger K, Misra S, Bassali RW, Davis CL. Lower uncarboxylated osteocalcin concentrations in children with prediabetes is associated with beta-cell function. J Clin Endocrinol Metab. 2011 Jul;96(7):E1092-9. doi: 10.1210/jc.2010-2731. Epub 2011 Apr 20."
            }, 
            {
                "PMID": "23616149", 
                "citation": "Gower BA, Pollock NK, Casazza K, Clemens TL, Goree LL, Granger WM. Associations of total and undercarboxylated osteocalcin with peripheral and hepatic insulin sensitivity and \u03b2-cell function in overweight adults. J Clin Endocrinol Metab. 2013 Jul;98(7):E1173-80. doi: 10.1210/jc.2013-1203. Epub 2013 Apr 24."
            }, 
            {
                "PMID": "23147574", 
                "citation": "Booth SL, Centi A, Smith SR, Gundberg C. The role of osteocalcin in human glucose metabolism: marker or mediator? Nat Rev Endocrinol. 2013 Jan;9(1):43-55. doi: 10.1038/nrendo.2012.201. Epub 2012 Nov 13. Review."
            }
        ], 
        "required_header": {
            "download_date": "ClinicalTrials.gov processed this data on June 04, 2014", 
            "link_text": "Link to the current ClinicalTrials.gov record.", 
            "url": "http://clinicaltrials.gov/show/NCT01972113"
        }, 
        "responsible_party": {
            "investigator_affiliation": "Georgia Regents University", 
            "investigator_full_name": "Norman Pollock", 
            "investigator_title": "Assistant Professor, Department of Pediatrics", 
            "responsible_party_type": "Principal Investigator"
        }, 
        "secondary_outcome": [
            {
                "description": "Coagulation-related parameters (i.e., activated thrombin and endogenous thrombin potential) will be assessed at baseline and 8 weeks to determine that vitamin K2 has no procoagulant effect.", 
                "measure": "Change in coagulation", 
                "safety_issue": "Yes", 
                "time_frame": "8 weeks"
            }, 
            {
                "description": "Adipokines leptin and adiponectin will be measured in fasting serum at baseline and 8 weeks to explore whether changes in serum adipokine concentrations are influenced by vitamin K2 supplementation.", 
                "measure": "Changes in serum adipokine concentrations", 
                "safety_issue": "No", 
                "time_frame": "8 weeks"
            }, 
            {
                "description": "Moderation effects of sex, race, bone age, and pubertal stage in the associations of vitamin K-induced changes in carboxylation of osteocalcin on markers of glucose metabolism will be determined.", 
                "measure": "Effects of sex, race, bone age, and pubertal stage on changes in glucose metabolism (insulin sensitivity and beta-cell function)", 
                "safety_issue": "No", 
                "time_frame": "8 weeks"
            }
        ], 
        "source": "Georgia Regents University", 
        "sponsors": {
            "collaborator": [
                {
                    "agency": "University of Alabama at Birmingham", 
                    "agency_class": "Other"
                }, 
                {
                    "agency": "Yale University", 
                    "agency_class": "Other"
                }, 
                {
                    "agency": "Tufts University", 
                    "agency_class": "Other"
                }, 
                {
                    "agency": "NattoPharma, ASA", 
                    "agency_class": "Other"
                }
            ], 
            "lead_sponsor": {
                "agency": "Georgia Regents University", 
                "agency_class": "Other"
            }
        }, 
        "start_date": "September 2013", 
        "study_design": "Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Prevention", 
        "study_type": "Interventional", 
        "verification_date": "October 2013"
    }
}